MVM Partners

📣 PRESS RELEASE - eXmoor and Virica Biotech receive funding to improve AAV gene therapy manufacturing 📣 We are delighted to announce this collaborative Canada-UK project aimed at improving the manufacture of adeno-associated vectors (#AAV), a crucial component of #genetherapies. We will utilize Virica’s VSEs™, small molecules that have been shown to increase productivity of AAVs, leveraging our scale-up and process development expertise to identify top candidates and deploy them at commercial scale upon completion of the project next year. “We thank Innovate UK for supporting this project, which we believe will benefit not only our work but our entire industry – and most importantly, patients,” said Angela Osborne “The advisory services and funding provided by the National Research Council Canada / Conseil national de recherches Canada Industrial Research Assistance Program and our partnership with eXmoor create a great commercial opportunity to increase efficiency and reduce costs of life-saving therapies,” said Jean-Simon Diallo, co-founder and CEO of Virica Read the full press release below. https://lnkd.in/eCjf55tV

Congratulations to MVM portfolio company Gynesonics, Inc. on its agreement to be acquired by Hologic, Inc.! https://lnkd.in/ePBMhwTe

News! We are pleased to announce that we have signed a definitive agreement to acquire Gynesonics, a developer of minimally invasive solutions for women’s health. Read more here: https://ow.ly/NJzZ50TKO3Y.

Gynesonics, Inc. is addressing a major unmet need in the treatment of uterine fibroids with its incisionless Sonata procedure, offering hope to millions of poorly-treated women. I feel confident that Hologic, Inc. can expand the availability of this remarkable procedure to women across the U.S. and globe. It has been a pleasure working with Skip Baldino, Robert Brown, MBA, CPA, and the entire talented, dedicated and passionate team at Gynesonics, Inc. https://lnkd.in/eBxCc2zc

Congratulations to eXmoor Pharma on its GMP manufacturing partnership with Quell Therapeutics to advance its cell therapy pipeline. https://lnkd.in/eVvQ7T-U

Exciting news for MVM portfolio company Vertos! https://lnkd.in/dWhHxq8p

https://lnkd.in/eQx5dTsV

We’re thrilled to announce that the Sonata® System has now been used to treat over 10,000 women worldwide! This achievement marks a significant step forward in advancing the standard of care for women with uterine fibroids. “Uterine fibroids can cause significant and debilitating symptoms, and many women suffer the symptoms rather than have invasive surgery. We are proud to offer a treatment that will preserve their uterus, without incisions and with a rapid recovery. This is the first of many milestones as we continually strive to advance the standard of women’s healthcare.” - Skip Baldino, President and Chief Executive Officer of Gynesonics Read the full press release here: https://lnkd.in/eczFhRVx #SonataSystem #WomensHealth #UterineFibroids #FibroidAwareness #HealthcareInnovation

We are delighted to announce that we have secured our MIA(IMP) license from the MHRA for the manufacture of cell & gene therapies for clinical trials. Our 65,000 sq. ft Cell & Gene Therapy Centre provides GMP cleanrooms and fill finish capabilities for autologous & allogenic cell therapies, viral vectors, RNA and other technologies! “This marks the beginning of a new era of growth for eXmoor pharma, now offering a complete set of development, manufacturing and expert consulting services that support cell and gene therapy developers from research to the market,” said Angela Osborne, CEO. “As we develop new partnerships, we will expand GMP operations to pivotal and commercial scale within the facility that is designed to increase cleanroom capacity quickly and easily – but we will retain the same underlying commitment to collaboration and focus on achieving our client's goals.” https://lnkd.in/eUZ9uGPp

We are thrilled to announce the publication of 'Clinical study of a micro-implantable pulse generator for the treatment of peripheral neuropathic pain: 3-month and 6-month results from the COMFORT-randomised controlled trial'. 88% of patients using Nalu PNS achieved ≥50% pain relief at 6 months (n=46) • Patients using Nalu PNS showed a 70% average pain reduction. • Outcomes were consistent across all anatomical areas in the study, including shoulder, low-back, knee, and foot/ankle pain. • Devices utilized Nalu advanced programming. “For the first time, interventional pain management clinicians can confidently provide SCS-level outcomes with a PNS system that is proven with RCT data,” said Dr. John Hatheway, lead author of the study and interventional pain medicine physician at Northwest Pain Care in Spokane, WA. “In addition to significant pain reduction, the COMFORT study demonstrated meaningful improvements in quality of life, mood, and functionality.” Congratulations to all of the authors! John Hatheway, Alexander P. Hersel, M.D., Jonathan Song, Mitch Engle, Genaro J. Gutierrez, MD, Vishal Khemlani, M.D., Leonardo Kapural, MD, PhD, Greg Moore, Reginald Ajakwe, Drew Trainor, Jennifer Hah, Peter Staats, MD, MBA, Paul Lynch, James Makous, PhD, Gary Heit Ph.D. M.D., Shilpa Kottalgi, Mehul J Desai Press release here: https://lnkd.in/d6Rakcmv These are Nalu outcomes. #NaluMed #PNS #COMFORT #Neuromodulation